A study of 20 people with obesity hinted at the possibility for semaglutide — the active ingredient in Type 2 diabetes drug Ozempic and weight-loss drug Wegovy — to increase the functionality of natural killer cells, which destroy cancerous cells.
Read the full post on Becker's Hospital Review - Healthcare News
